Background -Pseudomonas aeruginosa (PA) may cause suppurative otitis externa with severe inflammation and ulceration in dogs. Multidrug resistance is commonly reported for this organism, creating a difficult therapeutic challenge.
Introduction
Canine otitis externa is a common condition encountered in small animal medicine. Otitis is believed to be multifactorial and treatment can be difficult in some cases. [1] [2] [3] Common organisms isolated from dogs with otitis externa include Staphylococcus spp., Pseudomonas spp., Proteus spp., Streptococcus spp., Escherichia coli, Klebsiella spp., Bacteroides spp., Pasteurella spp. and Malassezia spp. Pseudomonas aeruginosa (PA) is an aerobic, Gram-negative bacillus which is associated with chronic otitis externa and otitis media, often leading to ulceration and inflammation within the ear canal. It is not considered part of the normal otic microflora, 4, 5 although data are available which support its low prevalence in healthy ears. 6, 7 Members of the genus Pseudomonas display a wide spectrum of innate resistance to several classes of antimicrobials 8 such as fluoroquinolones and aminoglycosides, in part because of the increasing frequency by which antimicrobials are prescribed. 9 Incomplete antimicrobial therapy readily selects for multidrug-resistant PA strains by mechanisms specific to each drug. Resistance to individual chemotherapeutic agents can be acquired via chromosomal mutations and/or lateral gene transfer. 10 Additionally, induction of a specific multidrug efflux system is observed upon exposure to sub-inhibitory concentrations of disinfectants such as chlorhexidine and benzalkonium. 11 Therefore, there is a need for more effective and convenient medical treatments. 12, 13 Antimicrobial peptides (AMP) could represent a promising alternative to conventional antimicrobials due to their wide activity and their low propensity to induce bacterial resistance.
14 AMPs belong to a broad family of cationic peptides that exert their bactericidal activity by destabilizing the bacterial membrane or increasing its permeability. 15 In the present study, in vitro antimicrobial activity of a commercial otic gel (Peptivet â oto gel ICF S.r.l.;
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The authors conducted this study with financial support from ICF s.r.l Cremona, Italy) which contains the novel antimicrobial peptide AMP2041, was tested against 30 canine otitis clinical isolates of PA and the P. aeruginosa ATCC27843 reference strain.
Materials and methods

Bacterial strains
Clinical isolates were obtained from cases of canine otitis externa during the period 2012-2015. All dogs were examined and sampled at the Parma University Veterinary Teaching Hospital. Otitis externa was diagnosed using cytology and cultural examination. Samples were collected from the horizontal canal with sterile swabs. Cytological examination showed large numbers of extra-and intracytoplasmic rods and highly degenerated neutrophils. In all cases, otoscopic examination showed presence of purulent exudate and intact tympanic membranes. Each swab was streaked to tryptose agar containing 5% bovine erythrocytes and McConkey agar plates (BD Difco; Sparks, MD, USA) in order to isolate PA. Isolates were identified to the species level using standard microbiological procedures, Gram staining and biochemical tests (API system, bioMerieux; Marcy l'Etoile, France). Thirty clinical isolates of PA, all derived from pure cultures, were collected. Isolates were stored on preservation beads (Oxoid, UK) at À80°C, then sub-cultured in Mueller Hinton Broth (BD Difco) and plated to tryptose agar/5% bovine erythrocytes prior to testing. ATCC P. aeruginosa reference strain 27853 was tested as a control.
In vitro susceptibility testing
Peptivet â oto gel is a commercial otological product containing 0.5 lg/mL of antimicrobial peptide AMP2041, 0.07% chlorhexidine digluconate, 0.4%Tris and 0.1% EDTA. The antimicrobial activity of AMP2041 has been reported previously 16, 17 on different bacterial and fungal species and in particular, on different PA clinical isolates and ATCC strain 27853. In the present study, the antimicrobial activity of the undiluted and diluted product was evaluated. Two-fold dilutions of Peptivet â oto gel were prepared in the range 1:2-1:256 with phosphate buffer (PB) 10 mM, pH 7. The minimum bactericidal concentration (MBC) for the reference strain and each clinical isolate was evaluated by broth microdilution assay, based on CLSI guidelines. 18 Briefly, for each strain the log-growth phase was reached while incubating bacteria in Mueller Hinton Broth at 37°C in a shaker at 225 r.p.m for 3-4 h. To standardize the inoculum, after pelleting at 1,000 g for 20 min, the bacterial suspension was adjusted in PB to obtain an optical density (OD) value at 600 nm in a 1 cm light path cuvette in the range 0.08-0.13, approximately equivalent to a 10 8 CFU/mL suspension. This suspension was further diluted 1:100 in PB. Fifty microlitres of the bacterial suspension containing 10 6 CFU/mL were inoculated into each well, to obtain a final concentration of 5 9 10 5 CFU/mL.
MBC evaluation
In order to evaluate the MBC for each strain, fifty microlitres of the diluted product were added to each well containing 50 lL of 10 6 CFU/mL bacterial suspension and incubated for 30 min at 37°C, after which 20 lL of each dilution was plated onto tryptose agar containing 5% bovine erythrocytes and incubated for 24 h at 37°C for CFU count. The MBC was defined as the lowest concentration that killed >99.9% of bacteria. For each strain, the standardized bacterial suspension was exposed to the MBC value of the product and incubated at 37°C for up to 48 h. Aliquots of 20 lL were withdrawn at fixed intervals (30 s, 1, 5, 10, 15 and 30 min, 24 and 48 h), and spread onto blood agar plates. After overnight incubation at 37°C, the CFU were counted and the inhibition percentages calculated compared to growth of the control for each isolate. All of the experiments were performed in triplicate. The persistence of antimicrobial activity of Peptivet â oto gel over time was evaluated for all strains by adding a fresh bacterial suspension to wells which underwent 24 and 48 h of incubation in the MBC evaluation assay.
Results
Minimal bactericidal concentration values for each clinical isolate and for the reference strain are shown in Table 1 . For ATCC strain 27853, the MBC after 30 min contact was obtained at the 1:64 dilution (corresponding to 0.008 lg/mL AMP2041, 0.001% CLX, 0.006% Tris, 0.002% EDTA). For the clinical strains the MBC was 1:64 for two of 30 strains, 1:128 (corresponding to 0.004 lg/ mL AMP2041, 0.0005% CLX, 0.003% Tris, 0.001% EDTA) for 15 of 30 strains and 1:256 (corresponding to 0.002 lg/mL AMP2041, 0.00025% CLX, 0.0015% Tris, 0.0005% EDTA) for 13 of 30 strains. The geometric mean was calculated to be 1:165, which is equivalent to a concentration of 0.0004% CLX + 0.0024%Tris + 0.0006% EDTA + 0.003 lg/mL AMP2041. The mean MBC for clinical isolates was therefore lower than the value for the ATCC 27853 strain.
Results for the time-to-kill assay are reported in Table 1 and Figure 1 . Time-to-kill assays performed with the undiluted product showed complete bactericidal effect for each clinical isolate and for the reference PA strain within 30 s (data not shown). Time-to-kill assays performed at each isolate's specific MBC value showed that complete bactericidal activity was reached within 5 min for 20 of 30 isolates, and within 30 min for all clinical isolates and the reference strain. An extended bactericidal activity of Peptivet â oto gel after 24 and 48 h of incubation in the MBC evaluation assay was observed (data not shown).
Discussion
Peptivet â oto gel showed microbicidal activity against 30 canine otitis clinical isolates of PA and the PA ATCC27843 reference strain. The MBC was at least equal to 1:64, as obtained for the reference strain and for two of 30 clinical isolates, and the MBC geometric mean for the clinical strains was equal to 1:165. For all strains, complete bactericidal activity was reached within 30 min when Peptivet â oto gel was tested at MBC concentrations.
This study has shown that Peptivet â oto gel, which combines AMP2041 with chlorhexidine, produces very good in vitro microbicidal activity against clinical isolates of P. aeruginosa, even when highly diluted (0.003 lg/mL AMP2041 and 0.0004% chlorhexidine). Maintenance of activity at diluted concentrations is an important feature for antimicrobial agents used on the skin and in the ear canals. 19, 20 A prior study of AMP2041 showed bactericidal effect against PA ATCC strain 27853 at an MBC value of 2.14 lg/mL after 2 h of contact time, 17 whereas reported MICs for chlorhexidine digluconate against PA range from 8 to >70 lg/mL. 21 Although Tris-EDTA alone is known to be bacteriostatic, its addition to topical products significantly lowers the MIC and MBC values for several antimicrobials. 22 Antimicrobial peptides could represent a promising alternative to traditional antimicrobial drugs. A synergistic antimicrobial effect for AMP2041 with chlorhexidine has been hypothesized, due to their similar modes of action. Both compounds are strongly cationic in nature and bind strongly to bacteria, causing surface membrane damage. 17 Cases of chlorhexidine resistance have been reported over the past 30 years. 23 According to the Committee for Veterinary Medicinal Products of the European Agency for the Evaluation of Medicinal Products, 24 chlorhexidine is bactericidal above 100 lg/mL. In veterinary medicine products, chlorhexidine digluconate is present at concentrations starting at 1.5% w/v (15 mg/mL) up to 4% w/v (40 mg/mL) and can be used with a dilution factor of around 1 part to 30. However, it has been suggested that the exposure of bacteria to chlorhexidine residual concentrations under the MIC value could lead to an increase in bacteria resistance. 21 Chlorhexidine cytotoxicity has been observed both in vitro and in vivo after contact. Human erythrocyte and neutrophil lysis at chlorhexidine concentrations above 2% have been demonstrated in vitro. 25 Nevertheless, chlorhexidine 0.20%, used in the ear canal with a perforated tympanic membrane in dogs did not induce cochlear or vestibular neurotoxicity. 26 Therefore, chlorhexidine toxicity may be related to its concentration. 27 On the basis of the data reported here, products which combine antimicrobial peptides with chlorhexidine present a potentially sound and novel approach to antiseptic treatment. The sustained killing time afforded by this combination may allow for less frequent application and improve owner compliance. The low concentration of each component drug may reduce the probability of toxicity, thereby enhancing tolerability. In conclusion, Peptivet â oto gel has a rapid and long-lasting in vitro activity against clinical isolates of P. aeruginosa. Randomized clinical trials are needed to prove its in vivo efficacy in the setting of canine Pseudomonas otitis. Resumen Introducci on -Pseudomonas aeruginosa (PA) puede causar otitis externa supurativa con inflamaci on y ulceraci on en perros. La resistencia a m ultiples f armacos se ha diseminado para este organismo, creando un desaf ıo terap eutico de dif ıcil soluci on Objetivo -El objetivo de este estudio fue evaluar la actividad antimicrobiana in vitro de un gel que contiene 0,5 mg / ml de p eptido antimicrobiano AMP2041, 0,07% de digluconato de clorhexidina (CLX), 0.4% Tris y 0,1% de EDTA en 30 aislados cl ınicos de PA de otitis externa canina. Materiales y M etodos -La actividad antimicrobiana se evalu o mediante la concentraci on bactericida m ınima (MBC). Suspensiones bacterianas estandarizadas se incubaron con diferentes concentraciones de gel a 37°C durante 30 min y se sembraron para evaluar la formaci on de unidades formadoras de colonia (CFU). La cin etica del tiempo para destruir los organismos fue evaluada con el producto sin diluir y a la MBC para cada cepa de PA a los 30 s, 1, 5, 10, 15, 30 min, 24 y 48 h. Resultados -La MBC fue 1:64 para dos cepas de 30 cepas, 1: 128 en 15 de 30 cepas y 1: 256 en 13 de 30 cepas. La media geom etrica fue de 1: 165, equivalente a una concentraci on de 0,003 mg / ml AMP2041 + 0,0004% CLX + 0,0024% Tris + 0,0006% EDTA. Los ensayos del tiempo transcurrido hasta destruir los organismos con el producto sin diluir mostraron un efecto bactericida completo dentro de los 30 primeros segundos para todos los aislados, mientras que a la MBC se produjo este efecto dentro de 5 minutos para 20 de los 30 aislados y dentro de 30 minutos para todos los aislados. La actividad bactericida se mantuvo despu es de 48 h para todos los aislados. Conclusi on -Este gel ha mostrado una actividad r apida, completa y duradera frente a un panel de 30 aislados de PA de casos de otitis externa canina. Resumo Contexto -Pseudomonas aeruginosa (PA) pode causar otite externa supurativa com inflamac ßão severa e ulcerac ßão em cães. Multirresistência e comumente relatada neste microrganismo, criando um dif ıcil desafio terapêutico. Objetivo -O objetivo deste estudo foi avaliar a atividade antimicrobiana in vitro de um gel contendo 0,5 µg/mL do pept ıdeo antimicrobiano AMP2041, digluconato de clorexidine (CLX) 0,07%, Tris 0,4% e EDTA 0,1% em 30 isolados cl ınicos de PA de otite externa de canina. Materiais e m etodos -Atividade antimicrobiana foi avaliada por concentrac ßão antimicrobiana m ınima (CAM). Suspensões bacterianas padronizadas foram incubadas com concentrac ßões diferentes do gel a 37 o C por 30 minutos e plaqueado para contagem de unidades formadoras de colônia (UFC). A cin etica de tempo de eliminac ßão foram avaliadas com o produto não dilu ıdo e em CAM para cada cepa de PA em 30 s, 1, 5, 10, 15, 30 min, 24 e 48 horas, Resultados -O CAM foi 1:64 para duas das 30 cepas, 1:128 para 15 de 30 cepas e 1:256 para 13 das 30 cepas. A m edia geom etrica foi 1:165, equivalente a concentrac ßão de 0,003 µg/mL AMP2041 + CLX 0,0004% + Tris 0,0024% + EDTA 0,0006%. Ensaios de tempo de eliminac ßão com o produto não dilu ıdo demonstrou efeito bactericida completo em 30 segundos para todos os isolados, enquanto no CAM, este efeito foi alcanc ßado em cinco minutos para 20 dos 30 islados e em 30 minutos para todos os isolados. Atividade bactericida foi mantida ap os 48 horas para todos os isolados. Conclusões -Este gel demonstrou atividade r apida, completa e duradoura contra um painel de 30 isolados de PA de casos de otite externa canina.
